牛牛AI助理已提取核心訊息
Bristol-Myers Squibb Company has announced the successful expiration of the Hart-Scott-Rodino (HSR) Act waiting period for its tender offer to acquire all outstanding shares of RayzeBio, Inc. The waiting period expired on February 9, 2024, satisfying one of the necessary conditions for the completion of the acquisition. The tender offer, priced at $62.50 per share in cash, values RayzeBio at approximately $4.1 billion. The transaction remains subject to the tender of a majority of RayzeBio's outstanding common stock and other customary closing conditions. The offer is set to expire on February 22, 2024, unless extended. This acquisition is part of Bristol-Myers Squibb's strategy to expand its portfolio in the biopharmaceutical sector, with RayzeBio focusing on radiopharmaceutical therapeutics for cancer treatment. Additionally, two complaints have been filed in federal court challenging certain disclosures related to the tender offer, which RayzeBio intends to defend vigorously. The announcement also included a joint press release issued by both companies on February 12, 2024.
Bristol-Myers Squibb Company has announced the successful expiration of the Hart-Scott-Rodino (HSR) Act waiting period for its tender offer to acquire all outstanding shares of RayzeBio, Inc. The waiting period expired on February 9, 2024, satisfying one of the necessary conditions for the completion of the acquisition. The tender offer, priced at $62.50 per share in cash, values RayzeBio at approximately $4.1 billion. The transaction remains subject to the tender of a majority of RayzeBio's outstanding common stock and other customary closing conditions. The offer is set to expire on February 22, 2024, unless extended. This acquisition is part of Bristol-Myers Squibb's strategy to expand its portfolio in the biopharmaceutical sector, with RayzeBio focusing on radiopharmaceutical therapeutics for cancer treatment. Additionally, two complaints have been filed in federal court challenging certain disclosures related to the tender offer, which RayzeBio intends to defend vigorously. The announcement also included a joint press release issued by both companies on February 12, 2024.
百時美施貴寶公司宣佈，收購RayzeBio, Inc.所有已發行股份的《哈特-斯科特-羅迪諾法案》（HSR）的等待期已成功到期。等待期於2024年2月9日到期，滿足了完成收購的必要條件之一。此次收購要約的現金價格爲每股62.50美元，對RayzeBio的估值約爲41億美元。該交易仍受RayzeBio大多數已發行普通股的投標和其他慣例成交條件的約束。除非延期，否則該優惠將於2024年2月22日到期。此次收購是百時美施貴寶擴大其在生物製藥領域的投資組合的戰略的一部分，RayzeBio專注於癌症治療的放射性藥物療法。此外，已向聯邦法院提起了兩起申訴，質疑與要約有關的某些披露，RayzeBio打算對此進行有力辯護。該公告還包括兩家公司於2024年2月12日發佈的聯合新聞稿。
百時美施貴寶公司宣佈，收購RayzeBio, Inc.所有已發行股份的《哈特-斯科特-羅迪諾法案》（HSR）的等待期已成功到期。等待期於2024年2月9日到期，滿足了完成收購的必要條件之一。此次收購要約的現金價格爲每股62.50美元，對RayzeBio的估值約爲41億美元。該交易仍受RayzeBio大多數已發行普通股的投標和其他慣例成交條件的約束。除非延期，否則該優惠將於2024年2月22日到期。此次收購是百時美施貴寶擴大其在生物製藥領域的投資組合的戰略的一部分，RayzeBio專注於癌症治療的放射性藥物療法。此外，已向聯邦法院提起了兩起申訴，質疑與要約有關的某些披露，RayzeBio打算對此進行有力辯護。該公告還包括兩家公司於2024年2月12日發佈的聯合新聞稿。
有用
沒用